Skip to main content

Table 1 Tau antibodies tested in preclinical efficacy studies

From: A walk through tau therapeutic strategies

ANTIBODY

EPITOPE

ANIMAL MODEL

IMPROVEMENT

EFFICACY

REFERENCE

Cognitive

Motor

NFTs

Insoluble tau

PHF1

pS396/404

P301L

nd.

nd.

nd.

Reduced

[56]

P301S

nd.

Improved

Reduced

Reduced

MC1

aa7–9 and aa 313–322

P301L

nd.

nd.

nd.

Reduced

P301S

nd.

Improved

Reduced

Reduced

MC1

aa7–9 and aa 313–322

P301L

nd.

nd.

Reduced

No change

[72]

DA31

aa150–190

No change

No change

PHF1

pSer396/404

Reduced

Reduced

4E6G7

379-408 (pS396/404)

P301L

nd.

nd.

Reduced

No change

[129]

6B2G12

TOMA

nd.

Tg2576

Improved

Improved

nd.

Reduced

[54]

PHF6

pT231

rTg4510

Improved

No change

nd.

No change

[281]

PHF13

pS396

rTg4510

Improved

No change

nd.

No change

PS19

Improved

nd.

Reduced

No change

HJ9.3

aa306–320

P301S

Improved

No change

Reduced

Reduced

[375]

HJ9.4

aa7–13

Moderate change

No change

Reduced

No change

HJ8.5

aa25–30

Moderate change

No change

Reduced

Reduced

HJ8.5

aa25–30

P301S

nd.

Improved

Reduced

Reduced

[374]

43D

aa6–18

3xTg-AD

Improved

nd.

Reduced

nd.

[73]

77E9

aa184–195

Improved

nd.

Reduced

nd.

AT8

pS202 + pT205

3xTg-AD

nd.

nd.

Reduced

nd.

[342]

MAb86

pS422

TauPS2APP

nd.

nd.

Reduced

nd.

[61]

pS404 mAb IgG2

pS404

K3 and pR5

nd.

nd.

Reduced

Reduced

[151]

pS409-tau

pS409

P301L

nd.

nd.

Reduced

Reduced

[182]

Armanezumab

aa2–18

THY-Tau22

nd.

nd.

Reduced

nd.

[4]

PHF1

pS396/404

P301L

nd.

Improved

Reduced

No change

[36]

Ta9

pS396

tau609

Improved

nd.

Reduced

Reduced

[328]

tau784

Ta4

pSer396

tau609

Improved

No change

Reduced

Reduced

tau784

Ta1505

pSer413

tau609

Improved

nd.

Reduced

Reduced

DC8E8

aa268-273, aa299-304, aa330-335, aa362-367

R3/m4

nd.

nd.

Reduced

Reduced

[168]

  1. nd Not defined